甲福明对阻塞性睡眠呼吸暂停患者的葡萄糖代谢和线粒体功能的影响:试点随机试验
Elizabeth R M Zunica1, Elizabeth C Heintz1, Wagner S Dantas1
1Integrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Physiological reports
|February 12, 2024
概括
在患有阻塞性睡眠呼吸暂停 (OSA) 的患者中,甲福明改善了葡萄糖代谢和骨肌肉功能,这表明它可能有助于预防糖尿病,当添加到正气道压力 (PAP) 治疗时.
科学领域:
- 内分泌学和新陈代谢学
- 睡眠医学 睡眠医学
- 线粒体生物学 线粒体生物学
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 与患糖尿病的风险增加有关.
- 标准的呼吸道正压 (PAP) 治疗OSA对葡萄糖代谢产生不一致的影响.
- 梅特福林对OSA患者骨肌肉线粒体的影响需要进一步调查.
研究的目的:
- 评估甲胺对中度至重度OSA患者葡萄糖代谢的影响.
- 为了评估甲福明对骨肌肉线粒体功能的影响,在这个患者群体.
- 为了确定甲福明是否可以防止与OSA相关的葡萄糖平衡下降.
主要方法:
- 一个双盲随机试验,涉及16名肥胖和中度至重度OSA的成年人.
- 参与者接受了PAP治疗,并被分配给甲福明或安慰剂3个月.
- 评估包括口服葡萄糖耐受性测试,骨肌肉活检以检测线粒体功能,以及蛋白质表达分析.
主要成果:
- 甲胺没有改变全身胰岛素敏感性 (马苏达指数),但与安慰剂相比,它阻止了胰岛素释放的增加.
- 胰岛素和胰岛素对葡萄糖的比率在安慰剂中增加,但在甲福林治疗中保持稳定.
- 甲胺增强了骨肌肉线粒体呼吸能力和动态.
结论:
- 在中度至重度OSA患者中,甲福明治疗有效地预防了全身葡萄糖平衡和骨肌肉线粒体功能的下降.
- 将甲福明添加到PAP治疗中可能有助于预防糖尿病的发展,从而使OSA患者受益.
- 甲胺对线粒体功能的积极影响需要进一步研究OSA管理.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
201
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
201
Sedatives and Hypnotics Drugs: Miscellaneous Agents
175
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
175
Insufficient Sleep and Sleep Deprivation
143
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
Sleep deprivation is a more severe form of sleep loss...
143
Management of Insomnia
248
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
248
Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187


